Crowdly
Add to Chrome
A client with chronic myelogenous leukemia is receiving filgrastim (Neupogen®) f...
✅ The verified answer to this question is available below. Our community-reviewed solutions help you understand the material better.
A client with chronic myelogenous leukemia is receiving filgrastim (Neupogen®) following bone marrow transplantation. Which of the following findings is unexpected with the administration of this medication?Reference Ranges:Platelets: 150,000-400,000 /mm³
Ramanpreet Kaur Sidhu ID: 137304
0%
0%
0%
✅